Best Brain Cancer Doctors in Hyderabad — CION's Coordinated Brain Tumor Pathway

Brain tumor treatment requires a coordinated team across multiple specialties: a neurosurgeon for surgery, a radiation oncologist for IMRT and stereotactic radiosurgery, and a medical oncologist for chemotherapy (typically temozolomide). The best ‘doctor’ is therefore the team — and the coordination between them. At CION, every brain tumor case is reviewed by a multidisciplinary tumour board, with radiation oncology led by Dr. Venkata Sushma P (MD SVIMS), medical oncology led by Dr. Owais Mohammed (MRCP SCE UK), and neurosurgery coordinated through accredited partner neurosurgical centres in Hyderabad.

This is the single most important first question. Benign brain tumors (meningiomas, pituitary adenomas, vestibular schwannomas / acoustic neuromas) are non-cancerous growths that often cause symptoms by pressing on brain structures rather than invading them. They are typically treated with surgery alone (or stereotactic radiosurgery for selected cases), and many are curable. Malignant brain tumors are cancers — primary brain cancers include gliomas (the most aggressive being glioblastoma / GBM), astrocytomas, and oligodendrogliomas. These typically require surgery + radiation + chemotherapy (Stupp protocol for GBM). A third category — metastatic brain tumors — is cancer that started elsewhere (lung, breast, melanoma, kidney, colon) and spread to the brain; in adults, this is far more common than primary brain cancer, and treatment is driven by the original cancer plus brain-directed radiation. Getting this classification right is the first job of the tumour board — and the treatment pathway is completely different for each.

Brain tumor surgery is performed by neurosurgeons — a distinct surgical specialty (M.Ch Neurosurgery) separate from general surgical oncology. CION coordinates neurosurgery through accredited partner neurosurgical centres in Hyderabad, with the surgical plan reviewed and integrated with CION's radiation oncology and medical oncology pathway through our multidisciplinary tumour board. After surgery, CION delivers the post-operative chemoradiation (Stupp protocol for GBM) and adjuvant chemotherapy directly. Long-term follow-up — including imaging surveillance and management of any recurrence — is coordinated between CION and the partner neurosurgical team. This is the same model used by most cancer centres in India for brain tumor management — radiation and medical oncology delivered at the cancer centre, neurosurgery coordinated with neurosurgical specialists.

The Stupp protocol is the standard treatment for newly diagnosed glioblastoma multiforme (GBM), established by Roger Stupp and colleagues in 2005. It consists of three phases: (1) maximal safe surgical resection of the tumour by a neurosurgeon, (2) concurrent radiation therapy (60 Gy over 6 weeks) plus daily oral temozolomide (TMZ) chemotherapy, and (3) six cycles of maintenance temozolomide chemotherapy after radiation completes. This protocol improved median survival in GBM from around 12 months to 14.6 months and has been the global standard of care for nearly 20 years. CION delivers the radiation and temozolomide phases of the Stupp protocol directly through our radiation oncology and medical oncology pathway, with the surgical phase coordinated through accredited partner neurosurgical centres.

Stereotactic radiosurgery (SRS) is a non-surgical radiation technique that delivers a high, precisely targeted dose of radiation to a small area, used most often for brain metastases (1–4 lesions), small benign tumors like vestibular schwannomas, and selected recurrent gliomas. SRS is delivered using Gamma Knife or CyberKnife or linear accelerator-based systems, typically in a single session. Compared to whole-brain radiation therapy, SRS preserves cognitive function and quality of life, which is why it has largely replaced whole-brain radiation for limited brain metastases. CION's radiation oncology pathway includes SRS delivered at our main hospital partner locations equipped with the appropriate technology. For metastatic brain disease, SRS is often the preferred approach over surgery or whole-brain radiation.

Brain metastases are treated very differently from primary brain cancers. The treatment plan is primarily driven by the original cancer (lung, breast, melanoma, kidney, colon) — not by the brain metastasis itself. Brain-directed therapy includes (1) stereotactic radiosurgery for 1–4 lesions (the modern preferred approach), (2) whole-brain radiation for multiple lesions, (3) surgical resection for solitary symptomatic lesions, and (4) systemic therapy that crosses the blood-brain barrier — including newer targeted agents and immunotherapy. CION's radiation oncology and medical oncology teams manage brain metastases across all primary cancer types as part of comprehensive cancer care.

Brain tumor treatment can affect cognitive function, personality, mood, and neurological function — both from the tumor itself and from treatment. Modern radiation techniques (IMRT, stereotactic radiosurgery) are designed to minimise radiation exposure to surrounding healthy brain tissue, which significantly reduces cognitive side effects compared to older whole-brain radiation. Temozolomide chemotherapy has relatively few cognitive side effects but can cause fatigue. Surgical resection in eloquent brain areas (controlling speech, movement, vision) requires careful planning — modern neurosurgical techniques (awake craniotomy, intraoperative neuromonitoring) help preserve function. Family members are often the best observers of subtle changes and should be involved in care planning.

Modern brain tumor diagnosis uses molecular classification (WHO 2021) in addition to traditional histology. Key markers include: IDH mutation status (IDH-mutant tumors have better prognosis than IDH-wildtype), 1p/19q co-deletion (signature of oligodendrogliomas, which have better prognosis), and MGMT promoter methylation (predicts better response to temozolomide chemotherapy). These markers affect both prognosis and treatment selection — for example, MGMT-methylated GBM responds better to temozolomide, and IDH-mutant astrocytomas have substantially longer survival than IDH-wildtype GBM. CION's pathology pathway includes molecular markers in line with current NCCN guidelines.

Pediatric brain tumors (medulloblastoma, ependymoma, pilocytic astrocytoma, diffuse intrinsic pontine glioma) are distinct from adult brain tumors — different biology, different treatment protocols, and different long-term considerations including growth, cognitive development, and endocrine function. Pediatric brain tumor care requires pediatric neurosurgery, pediatric oncology, and pediatric radiation oncology — typically only available at dedicated pediatric oncology centres. CION coordinates pediatric brain tumor cases with accredited partner pediatric oncology centres in Hyderabad. See our pediatric cancer doctors page for more on the pediatric cancer pathway.

A second opinion is especially valuable for brain tumors — particularly because surgical, radiation, and chemotherapy decisions vary across centres, and because the implications of treatment extend across years of cognitive function and quality of life. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your MRI, biopsy (if available), and existing recommendation and provides a documented opinion you can take anywhere.

Costs vary widely by tumour type and treatment. For GBM: neurosurgical resection (coordinated with partner centre) ranges approximately ₹2,50,000 to ₹6,00,000+; concurrent chemoradiation (Stupp protocol) ranges ₹3,00,000 to ₹6,00,000; six cycles of maintenance temozolomide ranges ₹1,00,000 to ₹3,00,000. For brain metastases: stereotactic radiosurgery (SRS / Gamma Knife / CyberKnife) ranges ₹1,50,000 to ₹4,00,000+ per treatment course. Benign brain tumors typically require only surgery (or SRS alone) — significantly lower total cost. For a detailed cost breakdown by treatment type, see our brain cancer treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate before treatment begins. Aarogyasri, EMI, and cashless insurance are accepted.